Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898282 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNASLC15A2MAPTMGAM | |
| SCHEMBL2051963 | 0.87 | MAPT (0.44) | ALDH1A1MAPT | |
| SCHEMBL2051964 | 0.87 | MAPT (0.44) | ALDH1A1MAPT | |
| SCHEMBL15260387 | 0.83 | LMNA (0.46) | ALDH1A1LMNASLC15A2MAPTTSHR | |
| SCHEMBL15274237 | 0.83 | LMNA (0.46) | ALDH1A1LMNASLC15A2MAPTTSHR | |
| SCHEMBL15260388 | 0.83 | LMNA (0.46) | ALDH1A1LMNASLC15A2MAPTTSHR | |
| SCHEMBL9899275 | 0.78 | ALDH1A1 (0.48) | ALDH1A1LMNASLC15A2HTTACHE | |
| SCHEMBL9899276 | 0.78 | ALDH1A1 (0.48) | ALDH1A1LMNASLC15A2HTTACHE | |
| SCHEMBL9899279 | 0.77 | — | — | |
| SCHEMBL21572634 | 0.77 | MAPT (0.39) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748531-B2 | Polymers functionalized with oxime compounds containing an acyl group | BRIDGESTONE CORPORATION (JP) | 2014-06-10 | — | — | US | claimed |
| EP-2649102-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | Bridgestone Corporation (JP) | 2013-10-16 | — | — | EP | claimed |
| US-20120149833-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | claimed |
| WO-2012078962-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | WO | claimed |
| EP-2920197-B1 | PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF | HARVARD COLLEGE (US) | 2021-03-17 | — | — | EP | disclosed |
| US-9617309-B2 | Proline-locked stapled peptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150239937-A1 | PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2649102-B1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | BRIDGESTONE CORP (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8748531-B2 | Polymers functionalized with oxime compounds containing an acyl group | BRIDGESTONE CORPORATION (JP) | 2014-06-10 | — | — | US | disclosed |
| EP-2649102-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | Bridgestone Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20120149833-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| WO-2012078962-A1 | POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239937-A1 | PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF | PRAP1, PRR12, NPPA | ALDH1A1 3816/4885LMNA 570/4885SLC15A2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.